Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- KALV
- Price
- 14.99
- Stock movement up
- +0.08 (0.54%)
- Company name
- Kalvista Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 757.69M
- Ent value
- 837.12M
- Price/Sales
- 50.12
- Price/Book
- 44.57
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 17.63%
- 1 year return (CAGR)
- 57.29%
- 3 year return (CAGR)
- 25.03%
- 5 year return (CAGR)
- -14.86%
- 10 year return (CAGR)
- 5.28%
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
KALV does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 50.12 |
| Price to Book | 44.57 |
| EV to Sales | 55.37 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 50.55M |
| EPS (TTM) | -3.90 |
| FCF per share (TTM) | -2.99 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 15.12M |
| Gross profit (TTM) | -2.60M |
| Operating income (TTM) | -203.03M |
| Net income (TTM) | -210.31M |
| EPS (TTM) | -3.90 |
| EPS (1y forward) | -2.79 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -17.16% |
| Operating margin (TTM) | -1342.96% |
| Profit margin (TTM) | -1391.14% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 243.50M |
| Net receivables | 7.12M |
| Total current assets | 325.23M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 339.93M |
| Accounts payable | 8.07M |
| Short/Current long term debt | 149.59M |
| Total current liabilities | 45.07M |
| Total liabilities | 322.93M |
| Shareholder's equity | 17.00M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -160.23M |
| Capital expenditures (TTM) | 791.00K |
| Free cash flow (TTM) | -161.02M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -1237.21% |
| Return on Assets | -61.87% |
| Return on Invested Capital | -1141.27% |
| Cash Return on Invested Capital | -873.77% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 14.82 |
| Daily high | 15.23 |
| Daily low | 14.22 |
| Daily Volume | 616K |
| All-time high | 126.56 |
| 1y analyst estimate | 33.78 |
| Beta | -0.35 |
| EPS (TTM) | -3.90 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| KALV | S&P500 | |
| Current price drop from All-time high | -88.16% | -1.82% |
| Highest price drop | -96.68% | -56.47% |
| Date of highest drop | 19 Oct 2022 | 9 Mar 2009 |
| Avg drop from high | -85.84% | -10.84% |
| Avg time to new high | 195 days | 12 days |
| Max time to new high | 2688 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
757.69M
Marketcap category
Small-cap
Description
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
Employees
270
Website
Investor relations
-
SEC filings
CEO
T. Andrew Crockett
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page